Shamburg News · 8-K filed Nov 10, 2026, 4:05 PM EST

Kura Oncology Reports Third Quarter 2026 Financial Results and Corporate Update

KURA · Kura Oncology, Inc.

  • Earnings
  • Financing
  • Other event
  • Materiality: high

Kura Oncology reported third quarter 2026 net product revenue of $13.9 million for KOMZIFTI and total revenue of $22.8 million, with a net loss of $70.2 million, or $0.78 per share. The company reported $492.1 million in cash, cash equivalents and short-term investments as of September 30, 2026, and updated its 2026 collaboration revenue guidance to $40 million to $45 million. The company also reported a financing agreement with affiliates of Oberland Capital providing up to $300 million in potential funding, of which $55 million was received at closing.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-455416.

Written from the filing by Shamburg Markets. Figures are as reported by the company.